Načítá se...
Oligonucleotide therapeutics in neurodegenerative diseases
Therapeutics that directly target RNAs are promising for a broad spectrum of disorders, including the neurodegenerative diseases. This is exemplified by the FDA approval of Nusinersen, an antisense oligonucleotide (ASO) therapeutic for spinal muscular atrophy (SMA). RNA targeting therapeutics are cu...
Uloženo v:
| Vydáno v: | RNA Biol |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Taylor & Francis
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6152438/ https://ncbi.nlm.nih.gov/pubmed/29560813 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15476286.2018.1454812 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|